TG Therapeutics announced impressive preliminary revenue figures for 2025 and provided guidance for 2026 during the 44th Annual J.P. Morgan Healthcare Conference.
The company's flagship product, BRIUMVI, demonstrated strong commercial performance in 2025, with substantial market share capture since launch.
TG Therapeutics outlined key development milestones for 2026, emphasizing revenue growth potential and pipeline expansion opportunities.
2025 Revenue Highlights
Preliminary total global revenue of approximately $616 million, with BRIUMVI U.S. net product revenue reaching $594 million for the full year.
2026 Revenue Guidance
Targeting total global revenue of $875-900 million in 2026, including expected BRIUMVI U.S. net product revenue of $825-850 million.
Development Milestones
Key milestones include ENHANCE trial data announcement, azer-cel Phase 1 data presentation, and pivotal data release for subcutaneous BRIUMVI.
- The strong revenue performance in 2025 reflects the success of BRIUMVI in the market, positioning TG Therapeutics for significant growth potential in the coming years.
- Guidance for 2026 indicates the company's confidence in sustaining revenue growth and expanding product reach through development milestones.
- The planned exploratory studies and pipeline expansion underscore TG Therapeutics' commitment to innovation and long-term value creation.
TG Therapeutics' robust financial performance in 2025 and optimistic revenue guidance for 2026 signal a promising outlook for investors and stakeholders. With ongoing development initiatives and market expansion plans, the company is poised for continued growth and value creation in the pharmaceutical sector.